Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.

Researchers documented a six per cent to nine per cent decline in grocery spending within the first six months of the GLP-1 ...

Therapist Debby Parker tried to lose weight for years without success. Then she discovered an online weight management ...

Her departure comes as the snacks maker faces challenges including higher cocoa costs, inflation that has curtailed product demand and the proliferation of GLP-1 weight-loss drugs.

Trusted by U.S. Physicians and Pharmacies and Available Nationwide. Take Control of Your Weight Loss Journey: How Does GLP-1 ...

A new report from AARP Public Policy Institute found that the top 25 drugs prescribed under Medicare Part D have nearly ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

The use of GLP-1 drugs sparked the term "Ozempic shaming" to describe the negative perceptions faced by those who choose ...